Meta- analysis of RCTs showed that only cyclosporine A provided a simultaneous great effect size of SMD on ICSI , pain , and frequency .
Amitriptyline at different dosages showed a great effect size of SMD on pain and urgency or on ICSI and frequency .
The results from the n RCTs showed that the most frequently adopted treatment is oral pentosan polysulfate and that the use of botulinum A toxin intradetrusorial injections in PBS/IC is increasing .
Limited evidence exists for the few treatments for PBS/IC .
The lack of definitive conclusions is due to the great heterogeneity in methodology , symptoms assessment , duration of treatment , and follow-up in both RCTs and n RCTs
CONTEXT Different types of behavioural , dietary , interventional , pharmacologic , and surgical therapies have been used to treat painful bladder syndrome/interstitial cystitis ( PBS/IC ) .
Because of the paucity of r and omised placebo-controlled studies on different treatments , an evidence -based management approach has not yet been developed .
OBJECTIVE To critically review and synthesize data from a wide range of current therapeutic approaches to PBS/IC , to quantify the effect size from r and omised controlled trials ( RCTs ) , and to reach clinical agreement on the efficacy of treatments for PBS/IC .
Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome.
PURPOSE We evaluated the safety and efficacy of intravesical liposomes , a mucosal protective agent , compared to oral pentosan polysulfate sodium for interstitial cystitis/painful bladder syndrome . MATERIAL S AND METHODS We performed a prospect i ve longitudinal study of the effect of 2 independent treatments ( intravesical liposomes and oral pentosan polysulfate sodium ) in patients with interstitial cystitis/painful bladder syndrome . Ten possible responses ( or measures ) to treatment were monitored at 3 time points , including baseline , and weeks 4 and 8 . A total of 24 patients with interstitial cystitis/painful bladder syndrome were evaluated in a 1:1 ratio to intravesical liposomes ( 80 mg/40 cc distilled water ) once weekly or to oral pentosan polysulfate sodium ( 100 mg ) 3 times daily for 4 weeks each . RESULTS No patient had urinary incontinence , retention or infection due to liposome instillation . There were no unanticipated adverse events and no significant worsening of symptoms during followup . Statistically significant decreases in urinary frequency and nocturia were observed in each treatment group . Statistically significant decreases in pain , urgency and the O'Leary-Sant symptom score were observed in the liposome group . Decreased urgency in the liposome group had the most profound effect of the ordinal measures . CONCLUSIONS Each glycosaminoglycan directed treatment seemed beneficial . Liposome intravesical instillation is safe for interstitial cystitis/painful bladder syndrome with potential improvement after 1 course of therapy for up to 8 weeks . Intravesical liposomes achieved efficacy similar to that of oral pentosan polysulfate sodium . Further large-scale placebo controlled studies are needed . Intravesical liposomes appear to be a promising new treatment for interstitial cystitis/painful bladder syndrome
Meta- analysis of RCTs showed that only cyclosporine A provided a simultaneous great effect size of SMD on ICSI , pain , and frequency .
Amitriptyline at different dosages showed a great effect size of SMD on pain and urgency or on ICSI and frequency .
The results from the n RCTs showed that the most frequently adopted treatment is oral pentosan polysulfate and that the use of botulinum A toxin intradetrusorial injections in PBS/IC is increasing .
Limited evidence exists for the few treatments for PBS/IC .
The lack of definitive conclusions is due to the great heterogeneity in methodology , symptoms assessment , duration of treatment , and follow-up in both RCTs and n RCTs
CONTEXT Different types of behavioural , dietary , interventional , pharmacologic , and surgical therapies have been used to treat painful bladder syndrome/interstitial cystitis ( PBS/IC ) .
Because of the paucity of r and omised placebo-controlled studies on different treatments , an evidence -based management approach has not yet been developed .
OBJECTIVE To critically review and synthesize data from a wide range of current therapeutic approaches to PBS/IC , to quantify the effect size from r and omised controlled trials ( RCTs ) , and to reach clinical agreement on the efficacy of treatments for PBS/IC .